The FDA on Aug. 16 approved...

...Teva Pharmaceuticals' generic competitor to Mylan's Epi-Pen. Mylan has faced criticism for increasing the price of Epi-Pen to over $600 in the past decade, but released its own generic version in 2016 at a lower price. Epi-Pen holds preferred-tier status for 51% of covered lives in the United States, and Mylan's generic is preferred for 59% of lives.